Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Francesco Paolo Russo, Ciro Celsa et al.|The Lancet Oncology|2023Cited by 184
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysisMaria Guarino, Andrea Casadei‐Gardini, Luca Viganò et al.|Digestive and Liver Disease|2018Cited by 61
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with SorafenibFrancesco Caputo, Andrea Casadei‐Gardini, Vincenzo Dadduzio et al.|PLoS ONE|2020Cited by 47
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Andrea Casadei‐Gardini, Massimo Iavarone et al.|Cancer Management and Research|2021Cited by 38